# Zr89 + PET Companion Trial

> **NCT05279027** · EARLY_PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 6 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** Zirconium Zr 89 Crefmirlimab Berdoxa

## Key facts

- **NCT ID:** NCT05279027
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-08
- **Primary completion:** 2025-05-06
- **Final completion:** 2025-05-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279027, "Zr89 + PET Companion Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05279027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*